Cairns Health
-13%
est. 2Y upside i
Your voice. Your health. We care.
Rank
#2631
Sector
Digital Health, AI Healthcare, Remote Patient Monitoring
Est. Liquidity
~4Y
Data Quality
Data: LowCairns Health has a compelling product and strong moat, but the lack of disclosed financials and stale 2021 valuation make equity upside highly speculative.
Last updated: July 19, 2026
Successful commercial launch of Luna drives rapid adoption, leading to a valuation expansion to $70M+ by 2028, assuming a 4x multiple on modest revenue.
Revenue grows slowly or not at all; valuation remains stagnant near $35M due to lack of traction, resulting in no upside for common equity after dilution.
Failure to raise additional funding or a down round wipes out common equity; preference stack of $35M+ leads to near-total loss for employees.
Preference Stack Risk
highFunding Intensity
0%Total funding of $35.1M is a significant overhang against an unknown but likely modest valuation, creating a high preference risk for common shareholders.
Dilution Risk
highWith no revenue and a 2021 round, the company likely needs to raise capital within 12-24 months, causing meaningful dilution of 20-25%.
Secondary Liquidity
noneNo secondary market transactions have been reported; liquidity is dependent on an exit event.
Questions to Ask at the Interview
Strategic questions based on Cairns Health's data — designed to show you've done your homework.
- 1
“What is the current ARR and month-over-month growth rate since Luna's commercial launch?”
- 2
“How does Cairns plan to address the regulatory pathway (FDA clearance) for its radar device?”
- 3
“What is the expected timeline for the next funding round, and what valuation does the board anticipate?”
Community
Valuation Sentiment
Our model estimates -13% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.